Clinical use of carbamazepine for bipolar disorders

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 16, 2005, Pages 2887-2902

  Wang, Po W ^a,b   Ketter, Terence A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anticonvulsants; Bipolar disorders; Carbamazepine; Mania

Indexed keywords

ADENOSINE A1 RECEPTOR; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DEMECLOCYCLINE; EPOXIDE HYDROLASE; FLUOXETINE; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; MUSCLE RELAXANT AGENT; NICOTINAMIDE; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; REPAGLINIDE; RISPERIDONE; RITONAVIR; SEDATIVE AGENT; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ZIPRASIDONE;

ABDOMINAL PAIN; ANTICONVULSANT ACTIVITY; ATAXIA; BIPOLAR DISORDER; BLEEDING; BLOOD TOXICITY; BONE MARROW DEPRESSION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DELAYED DRUG RELEASE; DIABETES MELLITUS; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MALAISE; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MOUTH ULCER; NAUSEA; NEUROTOXICITY; NYSTAGMUS; OBESITY; PETECHIA; RECEPTOR BLOCKING; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SKIN BRUISING; SKIN TOXICITY; SOMNOLENCE; SORE THROAT; STEVENS JOHNSON SYNDROME; TERATOGENESIS; UNITED STATES; WEIGHT GAIN;

BIPOLAR DISORDER; CARBAMAZEPINE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 29444435441     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.16.2887     Document Type: Review

References (147)

1. KESSLER RC, CHIU WT, DEMLER O, MERIKANGAS KR, WALTERS EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62(6):617-627.
2. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry (2002) 59(6):530-537.
3. OSBY U, BRANDT L, CORREIA N, EKBOM A, SPAREN P; Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry (2001) 58(9):844-850.
4. KUPFER DJ, FRANK E, GROCHOCINSKI VJ, CLUSS PA, HOUCK PR, STAPF DA: Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J. Clin. Psychiatry (2002) 63(2):120-125.
5. AMERICAN PSYCHIATRIC ASSOCIATION: Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry (2002) 159(4 Suppl.):1-50.
6. WEISLER RH, KALALI AH, KETTER TA: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry (2004) 65(4):478-484.
7. WEISLER RH, KECK PE Jr, SWANN AC, CUTLER AJ, KETTER TA, KALALI AH: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry (2005) 66(3):323-330.
8. SUPPES T, DENNEHY EB, HIRSCHFELD RM et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry (2005) 66(7):870-886.
9. BOWDEN CL, BRUGGER AM, SWANN AC et al.: Efficacy of divalproex versus lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA (1994) 271(12):918-924.
10. KELLER MB, LAVORI PW, CORYELL W et al.: Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA (1986) 255(22):3138-3142.
11. PRIEN RF, HIMMELHOCH JM, KUPFER DJ: Treatment of mixed mania. J. Affect. Disord. (1988) 15(1):9-15.
12. OKUMA T: Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology (1993) 27(3):138-145.
13. DUNNER DL, FIEVE RR: Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry (1974) 30(2):229-233.
14. DUNNER DL, FLEISS JL, FIEVE RR: The course of development of mania in patients with recurrent depression. Am. J. Psychiatry (1976) 133(8):905-908.
15. GOODNICK PJ, FIEVE RR, SCHLEGEL A, BAXTER N: Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate. Am. J. Psychiatry (1987) 144(3):367-369.
16. SWANN AC, BOWDEN CL, CALABRESE JR, DILSAVER SC, MORRIS DD; Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr. Scand. (2000) 101(6):444-451.
17. GELENBERG AJ, KANE JM, KELLER MB et al.: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med. (1989) 321(22):1489-1493.
18. ALBANESE MJ, BARTEL RL, BRUNO RF, MORGENBESSER MW, SCHATZBERG AF: Comparison of measures used to determine substance abuse in an inpatient psychiatric population. Am. J. Psychiatry (1994) 151(7):1077-1078.
19. POND SM, BECKER CE, VANDERVOORT R, PHILLIPS M, BOWLER RM, PECK CC: An evaluation of the effects of lithium in the treatment of chronic alcoholism: I. Clinical results. Alocohol. Clin. Exp. Res. (1981) 5(2):247-251.
20. NASRALLAH HA, CHURCHILL CM, HAMDAN-ALLAN GA: Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am. J. Psychiatry (1988) 145(11):1455-1456.
21. KANE JM, SMITH JM: Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry (1982) 39(4):473-481.
22. AHLFORS UG, BAASTRUP PC, DENCKER SJ et al.: Flupenthixol decanoate in recurrent manic-depressive illness: A comparison with lithium. Acta Psychiatr. Scand. (1981) 64(3):226-237.
23. BALLENGER JC, POST RM: Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun. Psychopharmacol. (1978) 2(2):159-175.
24. OKUMA T, KISHIMOTO A, INOUE K, MATSUMOTO H, OGURA A: Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: A preliminary report. Folia Psychiatr. Neurol Jpn. (1973) 27(4):283-297.
25. LAMBERT PA, CARRAZ G, BORSELLI S, CARBEL S: [Neuropsychotropic action of a new anti-epileptic agent: depamide]. Ann. Med. Psychol. (1966) 124(5):707-710.
26. ORTELLS MO, BARRANTES GE: Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br. J. Pharmacol. (2002) 136(6):883-895.
27. KETTER TA, FRYE MA, CORA-LOCATELLI G, KIMBRELL TA, POST RM: Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell. Mol. Neurobiol. (1999) 19(4):511-532.
28. KERR BM, THUMMEL KE, WURDEN CJ et al.: Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. (1994) 47(11):1969-1979.
29. EICHELBAUM M, TOMSON T, TYBRING G, BERTILSSON L: Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin. Pharmacokinet. (1985) 10(1):80-90.
30. NIGHTINGALE SL: From the Food and Drug Administration. JAMA (1990) 263(14):1896.
31. POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Correlates of antimanic response to carbamazepine. Psychiatry Res. (1987) 21(1):71-83.
32. EMRICH HM, DOSE M, VON ZERSSEN D: The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J. Affect. Disord. (1985) 8(3):243-250.
33. KLEIN E, BENTAL E, LERER B, BELMAKER RH: Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses: A controlled study. Arch. Gen. Psychiatry (1984) 41(2):165-170.
34. MÜLLER AA, STOLL KD: Carbamazepine and oxcarbzepine in the treatment of manic syndromes: studies in Germany. In: Anticonvulsants in Affective Disorders, HM Emrich, T Okuma, AA Müller (Eds), Excerpta Medica, Amsterdam, The Netherlands (1984):139-147.
35. GONCALVES N, STOLL KD: [Carbamazepine in manic syndromes: a controlled double-blind study]. Nervenarzt. (1985) 56(1):43-47.
36. DESAI NG, GANGADHAS BN, CHANNABASAVANNA SM, SHETTY KT: Carbamazepine hastens therapeutic action of lithium in mania: Proceedings of the International Conference on New Directions in Affective Disorders. Jerusalem, Israel (1987) (Abstract).
37. MÖLLER HJ, KISSLING W, RIEHL T, BAUML J, BINZ U, WENDT G: Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry (1989) 13(1-2):127-136.
38. OKUMA T, INANAGA K, OTSUKI S et al.: Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Pychopharmacology (1979) 66(3):211-217.
39. OKUMA T, YAMASHITA I, TAKAHASHI R et al.: A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr. Scand. (1989) 80(3):250-259.
40. OKUMA T, YAMASHITA I, TAKAHASHI R et al.: Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry (1990) 23(3):143-150.
41. GROSSI E, SACCHETTI E, VITA A et al.: Carbamazepine versus chlorpromazine in mania: a double-blind trial In: Anticonvulsants in Affective Disorders. HM Emrich, T Okuma, AA Müller (Eds), Excerpta Medica, Amsterdam, The Netherlands (1984):177-187.
42. STOLL KD, BISSON HE, FISCHER E et al.: Carbamazepine versus haloperidol in manic syndromes - first report of a multicentric study in Germany. In: Biol. Psychiatry 1985. C Shagass (Ed.), Elsevier, Amsterdam, The Netherlands (1986):332-334.
43. BROWN D, SILVERSTONE T, COOKSON J: Carbamazepine compared to haloperidol in acute mania. Int. Clin. Psychopharmacol. (1989) 4(3):229-238.
44. LERER B, MOORE N, MEYENDORFF E, CHO SR, GERSHON S: Carbamazepine versus lithium in mania: a double-blind study. J. Clin. Psychiatry (1987) 48(3):89-93.
45. SMALL JG, KLAPPER MH, MILSTEIN V et al.: Carbamazepine compared with lithium in the treatment of mania. Arch. Gen. Psychiatry (1991) 48(10):915-921.
46. LENZI A, LAZZERINI F, GROSSI E, MASSIMETTI G, PLACIDI GF: Use of carbamazepine in acute psychosis: a controlled study. J. Int. Med. Res. (1986) 14(2):78-84.
47. LUSZNAT RM, MURPHY DP, NUNN CM: Carbamazepine versus lithium in the treatment and prophylaxis of mania. Br. J. Psychiatry (1988) 153:198-204.
48. OKUMA T; Therapeutic and prophylactic effects of carbamazepine in bipolar disorders. Psychiatr. Clin. North Am. (1983) 6(1):157-174.
49. DILSAVER SC, SWANN AC, SHOAIB AM, BOWERS TC: The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. J. Psychiatry Neurosci. (1993) 18(2):61-66.
50. HIMMELHOCH JM: Cerebral dysrhythmia, substance abuse, and the nature of secondary affective illness. Psychiatric Annals (1987) 17:710-727.
51. HIMMELHOCH JM, GARFINKEL ME: Sources of lithium resistance in mixed mania. Psychopharmacol. Bull. (1986) 22(3):613-620.
52. NEUMANN J, SEIDEL K, WUNDERLICH HP: Comparative studies of the effect of carbamazepine and trimipramine in depression. In: Anticonvulsants in Affective Disorders. HM Emrich, T Okuma, AA Müller (Eds), Excerpta Medica, Amsterdam, The Netherlands (1984):160-166.
53. POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Antidepressant effects of carbamazepine. Am. J. Psychiatry (1986) 143(1):29-34.
54. SMALL JG: Anticonvulsants in affective disorders. Psychopharmacol. Bull. (1990) 26(1):25-36.
55. POST RM, ALTSHULER LL, KETTER TA, DENICOFF K, WEISS SR: Antiepileptic drugs in affective illness: clinical and theoretical implications. Adv. Neurol. (1991) 55:239-277.
56. HARTONG EG, MOLEMAN P, HOOGDUIN CA, BROEKMAN TG, NOLEN WA: Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J. Clin. Psychiatry (2003) 64(2):144-151.
57. OKUMA T, INANAGA K, OTSUKI S et al.: A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (1981) 73(1):95-96.
58. POST RM, UHDE TW, BALLENGER JC, SQUILLACE KM: Prophylactic efficacy of carbamazepine in manic-depressive illness. Am. J. Psychiatry (1983) 140(12):1602-1604.
59. PLACIDI GF, LENZI A, LAZZERINI F, CASSANO GB, AKISKAL HS: The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J. Clin. Psychiatry (1986) 47(10):490-494.
60. WATKINS SE, CALLENDER K, THOMAS DR, TIDMARSH SF, SHAW DM: The effect of carbamazepine and lithium on remission from affective illness. Br. J. Psychiatry (1987) 150:180-182.
61. COXHEAD N, SILVERSTONE T, COOKSON J: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr. Scand. (1992) 85(2):114-118.
62. BELLAIRE W, DEMISH K, STOLL KD: Carbamazepine versus lithium in prophylaxis of recurrent affective disorder. Psychopharmacology (1988) 96(Suppl.):287 (Abstract).
63. GREIL W, LUDWIG-MAYERHOFER W, ERAZO N et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomised study. J. Affect. Disord. (1997) 43(2):151-161.
64. MOSOLOV SN: [Comparative effectiveness of preventive use of lithium carbonate, carbamazepine and sodium valproate in affective and schizoaffective psychoses]. Zh. Neuropatol. Psikhiatr. Im. S S Korsakova. (1991) 91(4):78-83.
65. CABRERA JF, MUHLBAUER HD, SCHLEY J, STOLL KD, MULLER-OERLINGHAUSEN B: Long-term randomized clinical trial of oxcarbazepine versus lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry (1986) 19:282-283.
66. DENICOFF KD, SMITH-JACKSON EE, DISNEY ER, ALI SO, LEVERICH GS, POST RM: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiatry (1997) 58(11):470-478.
67. ELPHICK M, LYONS F, COWEN PJ: Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. J. Psychopharmacol. (1988) 2(1):1-4.
68. KISHIMOTO A, OKUMA T: Antimanic and prophylactic effects of carbamazepine in affective disorders. 4th World Congress of Biological Psychiatry, Philadelphia, PA, USA (1985).
69. DI COSTANZO E, SCHIFANO F: Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr. Scand. (1991) 83(6):456-459.
70. GREIL W, KLEINDIENST N, ERAZO N, MULLER-OERLINGHAUSEN B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J. Clin. Psychopharmacol. (1998) 18(6):455-460.
71. KETTER TA, KALALI AH, WEISLER RH: A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry (2004) 65(5):668-673.
72. MURPHY JM, MASHMAN J, MILLER JD, BELL JB: Suppression of carbamazepine-induced rash with prednisone. Neurology (1991) 41(1):144-145.
73. VICK NA: Suppression of carbamazepine-induced skin rash with Prednisone [letter). N. Engl. J. Med. (1983) 309(19):1193-1194.
74. KRAMLINGER KG, POST RM: Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am. J. Psychiatry (1990) 147(5):615-620.
75. RINGEL RA, BRICK JF: Perspective on carbamazepine-induced water intoxication: reversal by demeclocycline. Neurology (1986) 36(11):1506-1507.
76. BENTSEN KD, GRAM L, VEJE A: Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate. A controlled study. Acta Neurol. Scand. (1983) 67(4):235-241.
77. CONNELL JM, RAPEPORT WG, GORDON S, BRODIE MJ: Changes in circulating thyroid hormones during short-term hepatic enzyme induction with carbamazepine. Eur. J. Clin. Pharmacol. (1984) 26(4):453-456.
78. HAIDUKEWYCH D, RODIN EA: Chronic antiepileptic drug therapy: classification by medication regimen and incidence of decreases in serum thyroxine and free thyroxine index. Ther. Drug Monit. (1987) 9(4):392-398.
79. JOFFE RT, POST RM, BALLENGER JC, REBAR R, GOLD PW: Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia (1986) 27(2):156-160.
80. HERMAN R, OBARZANEK E, MIKALAUSKAS KM, POST RM, JIMERSON DC: The effects of carbamazepine on resting metabolic rate and thyroid function in depressed patients. Biol. Psychiatry (1991) 29(8):779-788.
81. O'NEILL B, CALLAGHAN N, STAPLETON M, MOLLOY W: Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol. Scand. (1982) 65(2):104-109.
82. BROWN DW, KETTER TA, CRUMLISH J, POST RM: Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J. Clin. Psychopharmacol. (1992) 12(6):431-437.
83. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry (2004) 65(2):267-272.
84. MATTSON RH, CRAMER JA, COLLINS JF: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N. Engl. J. Med. (1992) 327(11):765-771.
85. JONES KL, LACRO RV, JOHNSON KA, ADAMS J: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. (1989) 320(25):1661-1666.
86. ROSA FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. (1991) 324(10):674-677.
87. MATALON S, SCHECHTMAN S, GOLDZWEIG G, ORNOY A: The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod. Toxicol. (2002) 16(1):9-17.
88. WYSZYNSKI DF, NAMBISAN M, SURVE T, ALSDORF RM, SMITH CR, HOLMES LB: Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology (2005) 64(6):961-965.
89. WIDE K. WINBLADH B, KALLEN B: Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. (2004) 93(2):174-176.
90. MORROW JI, RUSSELL A, GUTHERIE E et al.: Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry (2005) (In press).
91. SITLAND-MARKEN PA, RICKMAN LA, WELLS BG, MABIE WC: Pharmacologic management of acute mania in pregnancy. J. Clin. Psychopharmacol. (1989) 9(2):78-87.
92. SHIMOYAMA R, OHKUBO T, SUGAWARA K: Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann. Clin. Biochem. (2000) 37(Pt 2):210-215.
93. FREY B, BRAEGGER CP, GHELFI D: Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann. Pharmacother. (2002) 36(4):644-647.
94. TOHEN M, CASTILLO J, BALDESSARINI RJ, ZARATE C Jr, KANDO JC: Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am. J. Psychiatry (1995) 152(3):413-418.
95. MCGINNESS J, KISHIMOTO A, HOLLISTER LE: Avoiding neurotoxicity with lithium-carbamazepine combinations. Psychopharmacol. Bull. (1990) 26(2):181-184.
96. KETTER TA, PAZZAGLIA PJ, POST RM: Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J. Clin. Psychopharmacol. (1992) 12(4):276-281.
97. TOHEN M, CASTILLO J, POPE H Jr, HERBSTEIN J: Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J. Clin. Psychopharmacol. (1994) 14(1):67-70.
98. KECK P Jr, MCELROY SL, VUCKOVIC A, FRIEDMAN LM: Combined valproate and carbamazepine treatment of bipolar disorder. J. Neuropsychiatry Clin. Neurosci. (1992) 4(3):319-322.
99. MACPHEE GJ, MITCHELL JR, WISEMAN L et al.: Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. Br. J. Clin. Pharmacol. (1988) 25:59-66.
100. MORELAND TA, CHANG SL, LEVY RH: Mechanisms of interaction between sodium valproate and carbamazepine in the rhesus monkey and in the isolated perfused rat liver. In: Metabolism of antiepileptic drugs. RH Levy et al. (Eds), Raven Press, New York, NY, USA (1984):53-60.
101. RAMBECK B, MAY T, JUERGENS U: Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther. Drug Monit. (1987) 9(3):298-303.
102. BRODIE MJ, FORREST G, RAPEPORT WG: Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br. J. Clin. Pharmacol. (1983) 16(6):747-749.
103. KUTT H, SOLOMON G, PETERSON H et al.: Accumulation of carbamazepine epoxide caused by valproate contributing to intoxication syndromes. Neurology (1985) 35(Suppl. 1):286-287.
104. KONDO T, OTANI K, HIRANO T, KANEKO S, FUKUSHIMA Y: The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br. J. Clin. Pharmacol. (1990) 29(1):116-119.
105. JANN MW, FIDONE GS, ISRAEL MK, BONADERO P: Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia (1988) 29(5):578-581.
106. SCHEFFNER D, KONIG S, RAUTERBERG-RULAND I, KOCHEN W, HOFMANN WJ, UNKELBACH S: Fatal liver failure in 16 children with valproate therapy. Epilepsia (1988) 29(5):530-542.
107. NAU H, LOSCHER W: Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl. Toxicol. (1986) 6(4):669-676.
108. YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry (2003) 182:141-147.
109. KAHN EM, SCHULZ SC, PEREL JM, ALEXANDER JE: Change in haloperidol level due to carbamazepine-a complicating factor in combined medication for schizophrenia. J. Clin. Psychopharmacol. (1990) 10(1):54-57.
110. JANN MW, FIDONE GS, HERNANDEZ JM, AMRUNG S, DAVIS CM: Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res. (1989) 28(2):153-159.
111. ERESHEFSKY L, JANN MW, SAKLAD SR, DAVIS CM: Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J. Clin. Psychiatry (1986) 47(9 Suppl.):6-15.
112. PITTERLE ME, COLLINS DM: Carbamazepine-10-11-epoxide evaluation associated with coadministration of loxapine or amoxapine. Epilepsia (1988) 29:654 (Abstract).
113. BROSEN K: Isozyme specific metabolism and interactions in psychopharmacology. 19th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington DC, USA (1994).
114. GRIMSLEY SR, JANN MW, CARTER JG, D'MELLO AP, D'SOUZA MJ: Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther. (1991) 50(1):10-15.
115. FRITZE J, UNSORG B, LANCZIK M: Interaction between carbamazepine and fluvoxamine. Acta Psychiatr. Scand. (1991) 84(6):583-584.
116. LAROUDIE C, SALAZAR DE, COSSON JP et al.: Carbamazepine-nefazodone interaction in healthy subjects. J. Clin. Psychopharmacol. (2000) 20(1):46-53.
117. SPINA E, AVENOSO A, POLLICINO AM, CAPUTI AP, FAZIO A, PISANI F: Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther. Drug Monit. (1993) 15(3):247-250.
118. STEINACHER L, VANDEL P, ZULLINO DF, EAP CB, BRAWAND-AMEY M, BAUMANN P: Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol. (2002) 12(3):255-260.
119. MOLLER SE, LARSEN F, KHANT AZ, ROLAN PE: Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J. Clin. Psychopharmacol. (2001) 21(5):493-499.
120. RAPEPORT WG, WILLIAMS SA, MUIRHEAD DC, DEWLAND PM, TANNER T, WESNES K: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry (1996) 57(Suppl. 1):20-23.
121. ANDERSEN BB, MIKKELSEN M, VESTERAGER A et al.: No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. (1991) 10 (2-3):201-203
122. CIUSANI E, ZULLINO DF, EAP CB, BRAWAND-AMEY M, BROCARD M, BAUMANN P: Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J. Psychopharmacol. (2004) 18(4):559-566.
123. KETTER TA, JENKINS JB, SCHROEDER DH et al.: Carbamazepine but not valproate induces bupropion metabolism. J. Clin. Psychopharmacol. (1995) 15(5):327-333.
124. JOFFE RT, POST RM, UHDE TW: Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine [letter]. Arch. Gen. Psychiatry (1985) 42(7):738.
125. YATHAM LN, BARRY S, MOBAYED M, DINAN TG: Is the carbamazepine-phenelzine combination safe? [letter]. Am. J. Psychiatry (1990) 147(3):367.
126. KETTER TA, POST RM, PAREKH PI, WORTHINGTON K: Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J. Clin. Psychiatry (1995) 56(10):471-475.
127. BARKLAGE NE, JEFFERSON JW, MARGOLIS D: Do monoamine oxidase inhibitors alter carbamazepine blood levels? [letter]. J. Clin. Psychiatry (1992) 53(7):258.
128. THWEATT RE: Carbamazepine/MAOI interaction [letter]. Psychosomatics (1986) 27(7):538.
129. LEINONEN E, LILLSUNDE P, LAUKKANEN V, YLITALO P: Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J. Clin. Psychopharmacol. (1991) 11(5):313-318.
130. BROSEN K, KRAGH-SORENSEN P: Concomitant intake of nortriptyline and carbamazepine. Ther. Drug Monit. (1993) 15(3):258-260.
131. BROWN CS, WELLS BG, COLD JA, FROEMMING JH, SELF TH, JABBOUR JT: Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. J. Clin. Psychopharmacol. (1990) 10(5):359-362.
132. BALDESSARINI RJ, TEICHER MH, CASSIDY JW, STEIN MH: Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs [letter]. J. Clin. Psychopharmacol. (1988) 8(5):381-382.
133. DE LA FUENTE JM, MENDLEWICZ J: Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol. Psychiatry (1992) 32(4):369-374.
134. LEMOINE A, GAUTIER JC, AZOULAY D et al.: Major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Mol. Pharmacol. (1993) 43(5):827-832.
135. OHMORI S, TAKEDA S, RIKIHISA T, KIUCHI M, KANAKUBO Y, KITADA M: Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol. Pharm. Bull. (1993) 16(6):571-575.
136. LAI AA, LEVY RH, CUTLER RE: Time-course of interaction between carbamazepine and clonazepam in normal man. Clin. Pharmacol. Ther. (1978) 24(3):316-323.
137. ARANA GW, EPSTEIN S, MOLLOY M, GREENBLATT DJ: Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. J. Clin. Psychiatry (1988) 49(11):448-449.
138. SEREE EJ, PISANO PJ, PLACIDI M, RAHMANI R, BARRA YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam. Clin. Pharmacol. (1993) 7(2):69-75.
139. GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, CIRAULO DA, SHADER RI: Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J. Clin. Psychiatry (1993) 54:4-11.
140. LEHTOVAARA R, BARDY A, HARI R, MAJURI H: Sodium valproate and clonazepam interactions with phenytoin and carbamazepine. In: Advances in Epileptology. H Meinardi, AJ Rowan (Eds), Swets and Zeitlinger, Amsterdam, The Netherlands (1978):269-270.
141. LANDER CM, EADIE MJ, TYRER JH: Interactions between anticonvulsants. Proc. Aust. Assoc. Neurol. (1975) 12:111-116.
142. VILLIKKA K, KIVISTO KT, LAMBERG TS, KANTOLA T, NEUVONEN PJ: Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br. J. Clin. Pharmacol. (1997) 43(5):471-474.
143. KUITUNEN T, MATTILA MJ, SEPPALA T, ARANKO K, MATTILA ME: Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br. J. Clin. Pharmacol. (1990) 30(3):453-461.
144. PAZZAGLIA PJ, POST RM, KETTER TA, GEORGE MS, MARANGELL LB: Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. (1993) 49(3):257-272.
145. PRICE WA, DIMARZIO LR: Verapamil-carbamazepine neurotoxicity [letter]. J. Clin. Psychiatry (1988) 49(2):80.
146. BRODIE MJ, MACPHEE GJ: Carbamazepine neurotoxicity precipitated by diltiazem. Br. Med. J. (1986) 292(6529):1170-1171.
147. TARTARA A. GALIMBERTI CA, MANNI R et al.: Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br. J. Clin. Pharmacol. (1991) 32(3):335-340.